MedTrace Logo

Efficacy and Safety Study of Ozanimod in Ulcerative Colitis

NCT01647516 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 199

Last updated 2021-05-19

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine whether RPC1063 is effective in the treatment of ulcerative colitis (UC).

Conditions

Interventions

DRUG

Ozanimod

Ozanimod capsules by mouth daily.

DRUG

Placebo

Sponsors & Collaborators

  • Celgene

    lead INDUSTRY

Principal Investigators

  • AnnKatrin Petersen, MD · Bristol-Myers Squibb

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
73 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-12-26
Primary Completion
2015-03-10
Completion
2019-08-30

Countries

  • United States
  • Australia
  • Belgium
  • Bulgaria
  • Canada
  • Greece
  • Hungary
  • Israel
  • Netherlands
  • New Zealand
  • Poland
  • Russia
  • Slovakia
  • South Korea
  • Ukraine

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01647516 on ClinicalTrials.gov